• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

    2/9/24 5:21:50 PM ET
    $AMPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AMPH alert in real time by email
    SC 13G/A 1 d748407dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 9)*

     

     

    AMPHASTAR PHARMACEUTICALS, INC.

    (Name of Issuer)

    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)

    03209R 10 3

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☒ Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 03209R 10 3    Page 2

     

     1   

     NAME OF REPORTING PERSON:

     

     Jack Yongfeng Zhang

     

     I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY:

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION:

     

     People’s Republic of China

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     4,223,156

       6  

     SHARED VOTING POWER

     

     9,212,054

       7  

     SOLE DISPOSITIVE POWER

     

     4,223,156

       8  

     SHARED DISPOSITIVE POWER

     

     9,212,054

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

     13,435,210 (1)

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

     26.2%(2)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

     IN

     

    (1)

    Includes (i) 1,876,046 shares of common stock held of record by Jack Yongfeng Zhang; (ii) 2,347,110 shares of common stock that are issuable upon exercise of outstanding options within 60 days of December 31, 2023 by Dr. Zhang; (iii) 1,368,546 shares of common stock held of record by Mary Luo, Dr. Zhang’s spouse; (iv) 1,015,829 shares of common stock that are issuable upon exercise of outstanding options within 60 days of December 31, 2023 by Dr. Luo; and (v) 6,827,679 shares of common stock held of record by Applied Physics & Chemistry Laboratories, Inc., or APCL, of which Dr. Zhang, Dr. Luo and The Bill Luobei Zhang 2004 Irrevocable Trust are the sole owners.

    (2)

    Based on 47,907,411 shares of the Issuer’s common stock outstanding as of November 2, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission on November 8, 2023.


    CUSIP No. 03209R 10 3    Page 3

     

     1   

     NAME OF REPORTING PERSON:

     

     Mary Ziping Luo

     

     I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY:

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION:

     

     United States of America 

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     2,384,375

       6  

     SHARED VOTING POWER

     

     11,050,835

       7  

     SOLE DISPOSITIVE POWER

     

     2,384,375

       8  

     SHARED DISPOSITIVE POWER

     

     11,050,835

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

     13,435,210(1)

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

     26.2%(2)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

     IN

     

    (1)

    Includes (i) 1,368,546 shares of common stock held of record by Mary Luo; (ii) 1,015,829 shares of common stock that are issuable upon exercise of outstanding options within 60 days of December 31, 2023 by Dr. Luo; (iii) 1,876,046 shares of common stock held of record by Jack Yongfeng Zhang, Dr. Luo’s spouse; (iv) 2,347,110 shares of common stock that are issuable upon exercise of outstanding options within 60 days of December 31, 2023 by Dr. Zhang; and (v) 6,827,679 shares of common stock held of record by Applied Physics & Chemistry Laboratories, Inc., or APCL, of which Dr. Zhang, Dr. Luo and The Bill Luobei Zhang 2004 Irrevocable Trust are the sole owners.

    (2)

    Based on 47,907,411 shares of the Issuer’s common stock outstanding as of November 2, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission on November 8, 2023.


    CUSIP No. 03209R 10 3    Page 4

     

     1   

     NAME OF REPORTING PERSON:

     

     Applied Physics & Chemistry Laboratories, Inc.

     

     I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY):

     

     33-4234397

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY:

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION:

     

     California

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     6,827,679

       6  

     SHARED VOTING POWER

     

     0

       7  

     SOLE DISPOSITIVE POWER

     

     6,827,679

       8  

     SHARED DISPOSITIVE POWER

     

     0

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

     6,827,679 (1)

    10  

     CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9):

     

     14.3%(2)

    12  

     TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

     CO

     

    (1)

    Jack Yongfeng Zhang, Mary Ziping Luo and The Bill Luobei Zhang 2004 Irrevocable Trust, the sole owners of Applied Physics & Chemistry Laboratories, Inc., or APCL, have shared voting and dispositive power over such shares.

    (2)

    Based on 47,907,411 shares of the Issuer’s common stock outstanding as of November 2, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2023, filed with the Securities and Exchange Commission on November 8, 2023.


    Item 1

    (a) Name of Issuer:

    Amphastar Pharmaceuticals, Inc.

    (b) Address of Issuer’s Principal Executive Offices:

    11570 6th Street

    Rancho Cucamonga, California 91730

    Item 2

    (a) Names of Persons Filing:

    Each of the following is a reporting person (“Reporting Person”):

    Jack Yongfeng Zhang

    Mary Ziping Luo

    Applied Physics & Chemistry Laboratories, Inc., or APCL

    (b) Address or principal business office or, if none, residence:

    The address for the principal business office of Dr. Zhang and Dr. Luo is:

    c/o Amphastar Pharmaceuticals, Inc.

    11570 6th Street

    Rancho Cucamonga, California 91730

    The address for the principal business office of APCL is:

    13760 Magnolia Avenue

    Chino, California 91710

    (c) Citizenship:

    Reference is made to the response to item 4 on each of pages 2-4 of this Schedule 13G (this “Schedule”), which  responses are incorporated herein by reference.

    (d) Title and Class of Securities:

    Common Stock, par value $0.0001 per share.

    (e) CUSIP No.:

    03209R 10 3

    Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

    Item 4. Ownership

    Reference is hereby made to the responses to items 5-9 and 11 of pages 2—4 of this Schedule, which responses are incorporated herein by reference.


    Item 5. Ownership of Five Percent or Less of a Class

    Not applicable.

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person

    Not applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not applicable.

    Item 8. Identification and Classification of Members of the Group

    Not applicable.

    Item 9. Notice of Dissolution of Group

    Not applicable.

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURES

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 9, 2024

     

    /s/ Jack Yongfeng Zhang

    Jack Yongfeng Zhang

    /s/ Mary Ziping Luo

    Mary Ziping Luo
    APPLIED PHYSICS & CHEMISTRY LABORATORIES, INC.
    By:  

    /s/ Jack Yongfeng Zhang

    Name: Jack Yongfeng Zhang
    Title:  President
    Get the next $AMPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AMPH

    DatePrice TargetRatingAnalyst
    5/12/2025$30.00Overweight → Neutral
    Analyst
    2/4/2025$66.00 → $36.00Overweight → Neutral
    Piper Sandler
    11/22/2024$55.00Equal Weight
    Wells Fargo
    3/5/2024$60.00Overweight
    JP Morgan
    11/17/2023$63.00Neutral
    BofA Securities
    7/25/2023$70.00Buy
    Jefferies
    10/21/2022$36.00Buy
    Jefferies
    7/29/2022$44.00Overweight
    CapitalOne
    More analyst ratings

    $AMPH
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for MEDROXYPROGESTERONE ACETATE issued to AMPHASTAR PHARMS INC

      Submission status for AMPHASTAR PHARMS INC's drug MEDROXYPROGESTERONE ACETATE (SUPPL-5) with active ingredient MEDROXYPROGESTERONE ACETATE has changed to 'Approval' on 01/25/2024. Application Category: ANDA, Application Number: 077334, Application Classification: Labeling

      1/26/24 4:40:02 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for CORTROSYN issued to AMPHASTAR PHARMS INC

      Submission status for AMPHASTAR PHARMS INC's drug CORTROSYN (SUPPL-33) with active ingredient COSYNTROPIN has changed to 'Approval' on 12/22/2023. Application Category: NDA, Application Number: 016750, Application Classification: Labeling

      12/27/23 4:38:39 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for NALOXONE HYDROCHLORIDE issued to AMPHASTAR PHARMS INC

      Submission status for AMPHASTAR PHARMS INC's drug NALOXONE HYDROCHLORIDE (SUPPL-1) with active ingredient NALOXONE HYDROCHLORIDE has changed to 'Approval' on 06/29/2023. Application Category: NDA, Application Number: 208969, Application Classification: Labeling

      6/30/23 9:33:25 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO & CHIEF SCIENTIFIC OFFICER Zhang Jack Y. exercised 200,000 shares at a strike of $13.03, increasing direct ownership by 8% to 2,847,659 units (SEC Form 4)

      4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

      6/16/25 5:19:35 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lee Howard was granted 5,122 shares and covered exercise/tax liability with 923 shares, increasing direct ownership by 3% to 151,976 units (SEC Form 4)

      4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

      6/4/25 8:04:41 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Deflin Gayle was granted 5,122 shares, increasing direct ownership by 88% to 10,914 units (SEC Form 4)

      4 - Amphastar Pharmaceuticals, Inc. (0001297184) (Issuer)

      6/4/25 7:45:15 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Amphastar Pharmaceuticals downgraded by Analyst with a new price target

      Analyst downgraded Amphastar Pharmaceuticals from Overweight to Neutral and set a new price target of $30.00

      5/12/25 8:19:14 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Amphastar Pharmaceuticals from Overweight to Neutral and set a new price target of $36.00 from $66.00 previously

      2/4/25 6:58:07 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on Amphastar Pharmaceuticals with a new price target

      Wells Fargo initiated coverage of Amphastar Pharmaceuticals with a rating of Equal Weight and set a new price target of $55.00

      11/22/24 7:19:52 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Comp

      1/8/25 6:00:00 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

      11/26/24 4:05:00 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

      11/13/24 4:05:00 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    SEC Filings

    See more
    • Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

      6/3/25 8:46:19 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Amphastar Pharmaceuticals Inc.

      10-Q - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

      5/8/25 4:24:18 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Amphastar Pharmaceuticals, Inc. (0001297184) (Filer)

      5/7/25 4:23:10 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

      3/6/24 10:23:26 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

      2/13/24 4:58:53 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Amphastar Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Amphastar Pharmaceuticals, Inc. (0001297184) (Subject)

      2/9/24 5:21:50 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AMPH
    Financials

    Live finance-specific insights

    See more
    • Amphastar Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / January 8, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Jack Zhang, CEO and President, and Bill Peters, CFO will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th, 2025, at 11:15 am PST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Comp

      1/8/25 6:00:00 AM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals to Present at the 36th Annual Piper Sandler Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / November 26, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Dan Dischner SVP of Corp. Communication, will participate in an Analyst-Moderated fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4th, 2024 at 11:30 am EST. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

      11/26/24 4:05:00 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference

      RANCHO CUCAMONGA, CA / ACCESSWIRE / November 13, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO, and Jacob Liawatidewi, EVP of Corporate Administration, will participate in an Analyst-Moderated fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 3:30 pm GMT. For access, visit Amphastar's Pharmaceuticals website at http://ir.amphastar.com. This webcast will be available for 30 days following the presentation.About Amphastar:Amphastar is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalatio

      11/13/24 4:05:00 PM ET
      $AMPH
      Biotechnology: Pharmaceutical Preparations
      Health Care